Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South Korea, Aug. 24, 2026 /PRNewswire/ -- Hanmi Pharm...
Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE), at Henry Ford Hospital in Detroit. Working...
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innovation hub designed to empower biotechnology companies to advance...
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today provided an overview of its interim results for the period...
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, to evaluate ABT-301 (Imofinostat), the Company's selective Class I histone...
Ceretone and Easter Seals Greater Houston Bring Hearing Technology to Local Seniors Through Community Initiative
Organizations came together to help seniors use technology with confidence and shape the future of hearing care HOUSTON, Aug. 21, 2026 /PRNewswire/ -- Ceretone, a direct-to-consumer hearing technology company, partnered with Easter Seals Greater Houston, Catholic Charities, and AmeriCorps Seniors to help seniors experience over-the-counter hearing technology in a supportive community setting while gathering valuable insights to improve...
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic growth momentum and sustainable earnings generation, with revenue reaching RMB 3.5882 billion, a 27.3% increase YoY, and net profit amounting to RMB 430.4 million, up 10.3% YoY. In the first...
LumenStim Prepares to Launch Next-Generation Teeth Whitening System on Kickstarter
Kickstarter-approved LumenStim Teeth Whitening System brings peroxide-free whitening into daily brushing as the company advances global patent applications for its oral-care technology. PLEASANTON, Calif., Aug. 21, 2026 /PRNewswire/ -- LumenStim, a beauty and wellness technology company recognized for its home-use phototherapy innovations, today announced that its highly anticipated peroxide-free at-home teeth whitening system has been approved to launch...
Coreline Soft and INFINITT North America Deploy Chest CT-Based AI Reading Workflow at St. Joseph’s Health
PHILLIPSBURG, N.J. and ATLANTA, Aug. 21, 2026 /PRNewswire/ -- Coreline Soft, a leading medical AI innovator, and INFINITT North America have announced the deployment of a chest CT-based AI reading workflow at St. Joseph's Health in Paterson, New Jersey. This marks the second major North American collaboration between the two companies, following their...
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based on CureGene's proprietary prodrug platform, incorporating precise design and structural optimization to achieve several key...
